Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Driggin, Elissa; Madhavan, Mahesh V.; Bikdeli, Behnood; Chuich, Taylor; Laracy, Justin; Biondi‐Zoccai, Giuseppe; Brown, Tyler S.; Nigoghossian, Caroline Der; Zidar, David A.; Haythe, Jennifer; Brodie, Daniel; Beckman, Joshua A.; Kirtane, Ajay J.; Stone, Gregg W.; Krumholz, Harlan M.; Parikh, Sahil A.

doi:10.1016/j.jacc.2020.03.031

Cited by 1,907 publications

(2,243 citation statements)

References 84 publications

Supporting

Mentioning

1,992

Contrasting

Unclassified

226

Order By: Relevance

“…(1,2) Cardiac complications of COVID-19 include myopericarditis, malignant arrhythmias, and biventricular heart failure. (3) In the largest case series to date of over 44,000 COVID-19 patients from China, the case fatality rate was significantly higher in those with preexisting CVD (10.5% vs 2.3%). (4) Patients with severe cases of COVID-19 frequently experience acute myocardial injury, as evidenced by elevated troponin levels, which is strongly associated with clinical deterioration (5) and increased mortality.…”

Section: Implications Of Covid-19 For Patients With Structural Heartmentioning

confidence: 95%

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

Chung

Nazif

Wolbinski

et al. 2020

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Patients with structural heart disease (SHD) are at increased risk of adverse outcomes from the coronavirus disease 19 (COVID-19) due to advanced age and comorbidity. In the midst of a global pandemic of a novel infectious disease, reality-based considerations comprise an important starting point for formulating clinical management pathways. The aim of these "crisisdriven" recommendations is (1) to ensure appropriate and timely treatment of SHD patients, (2) to minimize the risk of COVID-19 exposure to patients and healthcare workers, and (3) to limit resource utilization under conditions of constraint. While the degree of disruption to usual practice will vary across the United States and elsewhere, we hope that early experiences from a Heart Team operating in the current global epicenter of COVID-19 may prove useful for others adapting their practice in advance of local surges of COVID-19.

show abstract

Section: Implications Of Covid-19 For Patients With Structural Heartmentioning

confidence: 95%

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

Chung

Nazif

Wolbinski

et al. 2020

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…Drugs used for treatment of COVID-19 infection have many interactions with cardiovascular drugs and can also cause significant adverse cardiovascular effects. 3 Once this infection becomes more prevalent, all patients presenting with symptoms of severe emergent CVD should be managed as suspected cases of COVID-19. 4 Acute coronary syndrome (ACS) in COVID-19 infection is primarily attributed to demand supply mismatch.…”

Section: Managing Acs During Covid-19 Infection: Do Not Follow the Trmentioning

confidence: 99%

“…12 Hence, concomitant use of ticagrelor should be discouraged due to excess bleeding risk as has been done in USA and Canada. 3 Conversely, clopidogrel may not provide sufficient platelet inhibition during concomitant administration of lopinavir/ritonavir but this was not the case with prasugrel. 13,14 In case prasugrel cannot be used, testing guided approach with platelet function assays is strongly recommended.…”

Section: Managing Acs During Covid-19 Infection: Do Not Follow the Trmentioning

confidence: 99%

Managing ACS during COVID-19 infection: Do not follow the traditional route

Guha

Mukhopadhay

Karak

et al. 2020

Indian Heart Journal

View full text Add to dashboard Cite

“…L'atteinte cardiaque directe rapportée chez les patients hospitalisés est estimée entre 7 et 17 % en fonction des séries, et constitue 59 % des décès relatifs au SARS-COV 2 [5]. Néanmoins il s'agit des complications observées uniquement chez les patients hospitalisés et non pas sur l'ensemble des sujets infectés (Tableau 2).…”

Section: éPidémiologie Caractéristiques Cliniques Du Covid-19unclassified

“…D'autres statines comme l'atorvastatine et la rosuvastatine, peuvent être administré à des faibles doses [30]. Le Tableau 3 résume les interactions des antiviraux et les ajustements thérapeutiques possibles [5].…”

Section: Les Antivirauxunclassified